Hims & Hers Health shares rose by 5% on Tuesday following the company’s announcement that patients can now access Eli Lilly’s weight loss medication, Zepbound, along with the diabetes drug Mounjaro and the generic injection liraglutide, through its platform.
Zepbound, Mounjaro, and liraglutide belong to the GLP-1 class of weight loss medications, which have gained widespread popularity in recent years. Hims & Hers launched its weight loss program in late 2023, and its GLP-1 offerings have evolved as the company navigates a fluctuating supply and regulatory landscape.
According to the Hims & Hers website, Lilly’s weekly injections of Zepbound and Mounjaro will cost $1,899 per month for patients, while the generic liraglutide will cost $299 per month. However, liraglutide requires a daily injection and may be less effective than other GLP-1 medications.
“As we look ahead, we plan to continue to expand our weight loss offering to deliver an even more holistic, personalized experience,” Dr. Craig Primack, senior vice president of weight loss at Hims & Hers, shared in a blog post.
A Lilly spokesperson clarified that the company has “no affiliation” with Hims & Hers and highlighted that Zepbound is available at lower costs for insured individuals or those purchasing directly from the company.
In May, Hims & Hers began prescribing compounded semaglutide, the active ingredient in Novo Nordisk’s GLP-1 medications, Ozempic and Wegovy. This offering proved highly popular, generating over $225 million in revenue for the company in 2024. However, compounded medications are typically only mass-produced when branded treatments experience shortages. The U.S. Food and Drug Administration (FDA) declared in February that the shortage of semaglutide injections had been resolved, which meant Hims & Hers had to cease most compounded medications. Some consumers may still have access to personalized doses if deemed clinically necessary.
During its quarterly call with investors in February, Hims & Hers stated that its weight loss offerings would mainly focus on oral medications and liraglutide. The company forecasts its weight loss products will generate at least $725 million in annual revenue, excluding compounded semaglutide contributions.
Despite this, Hims & Hers continues to advocate for compounded medications. A pop-up on its website urges users to “use your voice” and encourage Congress and the FDA to preserve access to compounded treatments.
With the 5% rise in stock price, Hims & Hers shares are up approximately 27% in 2025, following a remarkable 172% increase last year.
